REGENESIS AND DSG COLLABORATE ON EDC WITH IWRS AND WEB-BASED ELECTRONIC PATIENT REPORTED OUTCOMES
MALVERN, Pa., September 9, 2014 Regenesis Biomedical, a medical technology company focused on energy-based therapeutics for pain management, has selected DSG’s eCaseLink as its provider for electronic data capture (EDC), web-based randomization, as well as eCaseLink.Me, DSG’s ePRO solution, for a new study of their previously approved PROVANT therapy in the treatment of post-operative pain.
DSG’s eCaseLink.Me is a highly affordable, proven, agency acceptable, fully-configurable electronic patient reported outcomes solution that is entirely web-based. It works on any browser or web-enabled device, so that patients may enter data conveniently from any wifi-enabled location. Regenesis Biomedical is experiencing the full benefit of specific eCaseLink.Me features such as auto emails, time controlled login, patient-configurable user-interface, and dynamic release of questionnaire all with zero training.
"This has been a great collaborative effort,” says Richard A Isenberg, MD, VP of Clinical and Regulatory Affairs for Regenesis Biomedical, Inc.
Read more »